2 Dividend Stocks to Buy and Hold For 10 Years

Bristol Myers Squibb and Amgen are pitched as durable, income-oriented buys despite near-term patent cliffs: BMS offers a 4.4% forward yield and has increased dividends 65.8% over the past decade, while Amgen yields over 3% and has raised its dividend annually since initiating in 2011. Both companies retain strong approved-product franchises (BMS oncology including Opdivo SC; Amgen's Tezspire, Tepezza, Repatha, Pavblu) and active pipelines that include BMS-986446 (FDA Fast Track for Alzheimer’s) and Amgen’s GLP-1 MariTide (phase 3) and bemarituzumab; these factors are argued to support revenue, earnings and dividend sustainability over the next ten years despite generic/biosimilar pressure.

Analysis

Market structure: Big-cap innovators (AMGN, BMY) stand to gain pricing power and steady cashflows as branded incumbents defend franchises vs biosimilars; beneficiaries also include partners like BNTX where co-development succeeds. Generics/biosimilar pure plays and small-cap oncology vendors face margin pressure as incumbents roll out reformulations (Opdivo SC) and biosimilar countermeasures, compressing pricing in commoditized segments within 12–36 months.

Risk assessment: Tail risks include an FDA failure in BMS-986446 or rapid biosimilar acceleration on Opdivo/Repatha that could knock 15–30% off valuations; a US drug-pricing reform shock is a major low-probability/high-impact event. Near term (0–6 months) watch trial readouts and patent litigation; medium-term (6–24 months) monitor biosimilar market share trends; long-term (2–5 years) hinge on successful new launches and M&A.

Trade implications: Favor conservatively sized core longs in AMGN (total return + dividends) and BMY for income, using covered calls to fund carry and 12–18 month LEAPs to play upside from successful approvals. Rotate 3–6% away from pure biotech growth ETFs into these dividend compounders; use put protection if positions exceed 3% portfolio weight to cap drawdowns >15%.

Contrarian angles: Market underestimates incumbents’ ability to defend pricing via reformulations and label expansions — Opdivo SC and Tezspire are non-linear revenue protectors. Historical parallel: big pharmas in 2010s successfully offset cliffs with M&A/pipeline and often oversold; if clinical readouts beat expectations, re-rate could be 20–40% over 12–24 months.

Key Decisions for Investors

• Establish a 1.5–2.5% long position in AMGN (buy in tranches over 4 weeks) as a 12–36 month core holding for 3%+ yield and pipeline optionality; fund by selling 6–9 month covered calls at ~10–12% OTM to generate ~2–4% premium, or buy 18-month LEAP calls 30% OTM (tick exposure capped to 1% notional).
• Establish a 2% long position in BMY for a 3–5 year income + recovery play, add another 1–2% if price falls >12% or forward yield rises above 5.2%; hedge initial position with a 6–9 month put 6% OTM if downside risk tolerance is exceeded (>15% loss threshold).
• Implement a relative-value pair: long AMGN (1.5%) vs short iShares Biotechnology ETF (IBB) (1.5% notional) to express preference for diversified drugmakers over high-beta biotech, rebalance quarterly and unwind if AMGN underperforms by >8% over 60 days.
• Trigger-based monitoring: if BMS-986446 posts a positive pivotal signal within 9–12 months, increase BMY exposure to 4% target; if FDA issues negative advisory or litigation causes >20% downside, reduce BMY to <0.5% and redeploy into AMGN or cash.